Naringenin alters the pharmacokinetics of ranolazine in part through the inhibition of cytochrome P450 (3A4) and P-glycoprotein

Abstract Background This study set out to look at how naringenin affected the pharmacokinetics of ranolazine in rats. The pharmacokinetic investigation rats following oral administration with or without coadministration was successfully conducted using established technique. Animals were administered same medications for 7 days as part a multiple dosage (MDS), and amount plasma calculated on 18 days. intestinal transit presence absence verapamil examined an vitro experiment sacs chickens (P-glycoprotein inhibitor). Results Naringenin raised maximal level (Cmax) from 231 ± 10.16 303.67 9.46 325.67 21.81 ng/mL SDS MDS, respectively. Moreover, elevated area under curve (AUC) 1293.54 37.18 1505.38 100.30 1575.42 76.98 ng/mL/h MDS. In naringenin, there increase transfer mucosal side serosal side. inhibits enzymes Cytochrome P450 (3A4) (CYP3A4) P-glycoprotein (P-gp). findings showed that might have considerable impact pharmacokinetics, including extending its t 1/2 raising AUC. Conclusions CYP3A4 P-gp. Therefore, Graphical abstract